Markets:

Overview

News

Currencies

International

Treasuries

BioCardia, Inc. - Common Stock (NQ:BCDA)

1.080 -0.020 (-1.82%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioCardia, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 22, 2023

Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private...

Via Benzinga

Recap: BioCardia Q1 Earnings ↗

May 10, 2023

Via Benzinga

BioCardia Earnings Preview ↗

May 09, 2023

Via Benzinga

BioCardia Earnings Perspective: Return On Capital Employed ↗

March 30, 2023

Via Benzinga

Earnings Outlook For BioCardia ↗

March 28, 2023

Via Benzinga

BioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study ↗

March 06, 2023

Via Benzinga

BioCardia's Return On Capital Employed Insights ↗

December 14, 2022

Via Benzinga

BioCardia's Heart Failure Cell Therapy Shows 100% Survival At Two Years ↗

October 03, 2022

Via Benzinga

$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying ↗

December 21, 2022

The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 08, 2022

Via Benzinga

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

December 06, 2022

From BioCardia, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022 ↗

November 11, 2022

Upgrades

Via Benzinga

Earnings Preview For BioCardia ↗

November 08, 2022

BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 09, 2022

Via Benzinga

Recap: BioCardia Q2 Earnings ↗

August 10, 2022

BioCardia (NASDAQ:BCDA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

FDA Approves BioCardia's Phase 1 Trial With Cell Therapy In COVID-19, Shares Jump ↗

April 12, 2022

Via Benzinga

BioCardia Earnings Preview ↗

August 09, 2022

BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will...

Via Benzinga

Executives Buy Around $4M Of 5 Penny Stocks ↗

May 16, 2022

US stock futures traded slightly lower this morning on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or...

Via Benzinga

Recap: BioCardia Q1 Earnings ↗

May 11, 2022

BioCardia (NASDAQ:BCDA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings BioCardia beat estimated earnings by...

Via Benzinga

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗

May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Preview For BioCardia ↗

May 10, 2022

BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that BioCardia will...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 06, 2022

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.

Via Benzinga

Follow the Insiders and Buy the Dip in These 3 Stocks ↗

May 06, 2022

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 25, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 21, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

April 19, 2022

Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

Benzinga's Daily Brief On Trending Tickers For April 12, 2022: Veru, Kohl's Corporation, BioCardia, And More ↗

April 12, 2022

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 04, 2022

Via Benzinga

Looking Into BioCardia's Return On Capital Employed ↗

March 30, 2022

Benzinga Pro data, BioCardia (NASDAQ:BCDA) reported Q4 sales of $79.00 thousand. Earnings fell to a loss of $3.46 million, resulting in a 27.9% decrease from last quarter.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.